Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Famotidine,Calcium Carbonate,Magnesium Hydroxide
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Akums Launches Dual Action Heartburn Relief Chewable Tablet
Details : Dual action heartburn relief chewable tablet, consisting Famotidine (H2 receptor antagonist), Calcium Carbonate and Magnesium Hydroxide have been approved and launched in indian market.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2024
Lead Product(s) : Famotidine,Calcium Carbonate,Magnesium Hydroxide
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rabeprazole Sodium,Levosulpiride
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Akums Launches Rabeprazole + Levosulpiride SR Capsules for GERD in India
Details : Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase, indicated for treating gastric and duodenal ulcers, as well as GERD.
Product Name : Rabeprazole-Levosulpiride-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 06, 2024
Lead Product(s) : Rabeprazole Sodium,Levosulpiride
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tamsulosin,Tadalafil
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Akums Introduces Tamsulosin + Tadalafil Capsule — to the Indian Market
Details : DCGI has approved Tamsulosin (selective alpha1A-adrenergic receptor antagonist) + Tadalafil, a fixed dose combination within a hard gelatin capsule for the treatment of erectile dysfunction & benign prostatic hyperplasia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 15, 2023
Lead Product(s) : Tamsulosin,Tadalafil
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sitagliptin Phosphate,Metformin,Pioglitazone
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Akums Gets DCGI Nod for Triple Combination Diabetes Medication
Details : Sitagliptin, Pioglitazone & Metformin are combined for the treatment of diabetes. Metformin, coupled with the functional and corrective influence of pioglitazone on beta-cell and metabolic syndrome and the stability of Sitagliptin, make an effective solu...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 27, 2023
Lead Product(s) : Sitagliptin Phosphate,Metformin,Pioglitazone
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lobeglitazone
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Akums Receives DCGI Approval for Type 2 Diabetes Drug to Improve Insulin Resistance
Details : Lobeglitazone is a film-coated tablet made up of Lobeglitazone Sulfate equivalent to Lobeglitazone to improve glycaemic control in adult type 2 diabetes.
Product Name : Lobeglitazone-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 02, 2023
Lead Product(s) : Lobeglitazone
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Lyrus Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Akums, Lyrus Life Sciences Collaborate for Patented Technologies and Formulations
Details : Akums and Lyrus will ensure the launch of patented drugs and more patient-friendly formulations, in the areas of pain, obesity, diabetes, psoriasis, seasonal flu, respiratory insufficiency, immunity and women’s health with a special focus on geriatric ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 22, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Lyrus Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Biophore India Pharmaceuticals Pvt Ltd
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership aims to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas, within the next five years, both in India and other global markets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 12, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Biophore India Pharmaceuticals Pvt Ltd
Deal Size : Undisclosed
Deal Type : Partnership
Reset All
